Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL28157733 | 1.00 | DAO (0.47) | DAOTSHRNAPRTALDH1A1KDM4E | |
| Benzoic Acid SCHEMBL1249516 | 0.98 | DAO (0.48) | DAOTSHRNAPRTALDH1A1KDM4E | |
| Benzoic Acid SCHEMBL4657369 | 0.98 | DAO (0.48) | DAOTSHRNAPRTALDH1A1KDM4E | |
| Benzoic Acid SCHEMBL28410519 | 0.98 | DAO (0.48) | DAOTSHRNAPRTALDH1A1KDM4E | |
| Benzoic Acid SCHEMBL5161411 | 0.97 | DAO (0.47) | DAOTSHRNAPRTALDH1A1KDM4E | |
| Benzoic Acid SCHEMBL29136455 | 0.97 | DAO (0.47) | DAOTSHRNAPRTALDH1A1KDM4E | |
| Benzoic Acid SCHEMBL17687656 | 0.97 | DAO (0.47) | DAOTSHRNAPRTALDH1A1KDM4E | |
| Terephthalic Acid SCHEMBL28411701 | 0.91 | TSHR (0.44) | TSHRALDH1A1KDM4EHPGDSRD5A2 | |
| Terephthalic Acid SCHEMBL28411703 | 0.91 | TSHR (0.44) | TSHRALDH1A1KDM4EHPGDSRD5A2 | |
| SCHEMBL29090785 | 0.89 | EGFR (0.49) | ALDH1A1KDM4EHPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067405-B2 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | NOVARTIS AG (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8003635-B2 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | NOVARTIS AG (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20110105453-A1 | Superoxide Dismutase Mimics For The Treatment Of Optic Nerve And Retinal Damage | ALCON, INC. (CH) | 2011-05-05 | — | — | US | disclosed |
| EP-1567166-B1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | ALCON INC (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100204194-A1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | ALCON, INC. (CH) | 2010-08-12 | — | — | US | disclosed |
| US-7759333-B2 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | ALCON, INC. (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20100179117-A1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | ALCON, INC. (CH) | 2010-07-15 | — | — | US | disclosed |
| US-7754706-B2 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | ALCON, INC. (CH) | 2010-07-13 | — | — | US | disclosed |
| EP-1463563-B1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | ALCON INC (CH) | 2009-02-18 | — | — | EP | disclosed |
| EP-1581212-A4 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | ALCON INC (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-20060035880-A1 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | disclosed |
| EP-1581212-A2 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | Alcon, Inc. (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005060974-A1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OPTIC NERVE AND RETINAL DAMAGE | ALCON, INC. (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-20050130951-A1 | Superoxide dismutase mimics for the treatment of optic nerve and retinal damage | ALCON, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050032768-A1 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | NOVARTIS AG (CH) | 2005-02-10 | — | — | US | disclosed |
| EP-1463563-A1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | Alcon, Inc. (CH) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004052227-A2 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | ALCON, INC. (CH) | 2004-06-24 | — | — | WO | disclosed |
| US-20040116402-A1 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | ALCON, INC. (CH) | 2004-06-17 | — | — | US | disclosed |
| US-20040116403-A1 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | ALCON, INC. (CH) | 2004-06-17 | — | — | US | disclosed |
| WO-2003051458-A1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | ALCON, INC. (CH) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035880-A1 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | SOD3, SOD1, CAT | DAO 307/4885TSHR 2387/4885NAPRT 2332/4885 |
| US-20050032768-A1 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | SOD3, SOD1, CAT | DAO 312/4885TSHR 1531/4885NAPRT 2853/4885 |
| US-20050130951-A1 | Superoxide dismutase mimics for the treatment of optic nerve and retinal damage | SOD1, SOD3, CAT | DAO 339/4885TSHR 2128/4885NAPRT 2136/4885 |
| US-20110105453-A1 | Superoxide Dismutase Mimics For The Treatment Of Optic Nerve And Retinal Damage | SOD1, SOD3, CAT | DAO 339/4885TSHR 2128/4885NAPRT 2136/4885 |
| US-20100204194-A1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | SOD3, SOD1, CAT | DAO 185/4885TSHR 1542/4885NAPRT 3212/4885 |
| US-20100179117-A1 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES | SOD3, SOD1, CAT | DAO 307/4885TSHR 2387/4885NAPRT 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.